Mani Furuhar's questions to Arrowhead Pharmaceuticals Inc (ARWR) leadership • Q3 2025
Question
Mani Furuhar's representative asked about the upcoming ARO-INHBE obesity data, specifically which cohorts would be included and what the company hopes to see relative to other muscle-sparing agents.
Answer
Management confirmed that data from single-ascending dose, multiple-ascending dose, and combination cohorts will be presented. The data will include various biomarkers, body composition changes measured by MRI, weight loss, and effects on lipid and glycemic parameters.